您的位置: 首页 > 文字全文
2023年7月 第38卷 第7期11
目录

基于口腔-肠道微生物轴探讨中医药防治动脉粥样硬化的研究进展

Research Progress on the Prevention and Treatment of Atherosclerosis by Traditional Chinese Medicine Based on the Oral-Gut Microbiota Axis

来源期刊: 广州医药 | - 发布时间: 收稿时间:2026/6/4 18:09:40 阅读量:91
作者:
关键词:
动脉粥样硬化 口腔菌群 肠道微生物 中医药 代谢产物 黏膜屏障
Atherosclerosis; Oral microbiota; Gut microbiota; Traditional Chinese Medicine; Metabolites; Mucosal barrier
DOI:
收稿时间:
 
修订日期:
 
接收日期:
 
引用总数:
0  
动脉粥样硬化(AS)是心血管疾病的病理基础,口腔与肠道通过菌群移位、代谢互作及免疫联动共同构成口腔-肠道微生物轴,其稳态失衡通过菌群易位、代谢紊乱和屏障损伤等促进AS发生发展。中医药以整体观念与辨证论治为指导,多靶点调控口腔-肠道微生物平衡,抑制血管炎症与脂质沉积,发挥抗AS效应。本文系统阐述口腔-肠道微生物与AS的关联,探讨中医药调控微生态防治该病的研究进展,分析当前研究存在的局限并展望未来方向,为中医药防治AS提供新的思路与理论依据。
Atherosclerosis (AS) is the pathological basis of cardiovascular diseases. The oral cavity and the gut together constitute the oral-gut microbial axis through microbial translocation, metabolic interactions, and immune crosstalk. Dysbiosis of this axis promotes the occurrence and development of AS via bacterial translocation, metabolic disorders, and barrier damage. Guided by the holistic concept and syndrome differentiation-based treatment, traditional Chinese medicine (TCM) exerts anti-AS effects by multi-target regulation of the oral-gut microbial balance, inhibiting vascular inflammation and lipid deposition. This article systematically elaborates the association between the oral-gut microbiota and AS, explores the research progress of TCM in modulating microecology for the prevention and treatment of AS, analyzes the limitations of current studies, and prospects future directions, so as to provide new insights and theoretical basis for TCM in preventing and treating AS.
1、重大疾病治疗重点专科建设(国家中医优势专科)项目(辽中医药发〔2022〕2 号)(/upload/408026/20260604/20260604172026_9385.pdf)
上一篇
下一篇
出版者信息








《广州医药》公众号
目录